Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor Combinations in MDS/MPN Overlap Syndrome
NCT06664970Phase 2Enrolling by invitation
- Sponsor
- Peking Union Medical College Hospital
- Start
- Nov 2024
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of selinexor in myelodysplastic/myeloproliferative neoplasm (MDS/MPN), sponsored by Peking Union Medical College Hospital. Primary endpoint: Overall Response Rate at 6 months. Started Nov 2024; status: enrolling by invitation.
02
Drugs
selinexor
03
Conditions
myelodysplastic/myeloproliferative neoplasm (MDS/MPN)
Beyond the preview
Go deeper on NCT06664970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06664970.